Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study
Laura Frederiksen, Shradha Subedi, Keat Choong, James Anderson, Timothy Baird · 2026
Read Respiratory and bloodstream coinfections and antimicrobial use in hospitalised patients with moderate to severe COVID-19: An Australian retrospective cohort study by Laura Frederiksen, Shradha Subedi, Keat Choong, James Anderson, Timothy Baird (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0352344.txt.
Description
Laura Frederiksen and four colleagues report this 2026 PLOS One study of extra infections in patients admitted to an Australian hospital in 2022 with COVID-19 classed as moderate to severe. Knowing how often bacteria, fungi, or other viruses join the initial infection matters for antibiotic decisions. The team reviewed one hundred ninety admissions, comparing patients with and without documented coinfection.
Only about one in eight patients had a coinfection, most often bacterial, yet three-quarters received antibiotics, typically for six days. Patients with coinfection stayed in hospital longer, though death rates did not differ. Intensive care patients and those with severe disease were more likely to have coinfection. The authors call the antibiotic use disproportionate and urge better testing so treatment matches actual infection.
Catalog record
| CREATOR | Laura Frederiksen, Shradha Subedi, Keat Choong, James Anderson, Timothy Baird |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 32345 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |